Patrick Kearney Email & Phone Number

San Diego, Ca, Us

La Jolla, Ca, Us

San Diego, California, Us

Headed the early R&D efforts to discover new and potentially best in class therapeutics that incorporate January's innovative albumin nano-formualtion technology to target treatments more specifically to cancer tissues.

Waltham, Massachusetts, Us

Worked as the chemistry lead investigator on an interdisciplinary research team to identify and optimize kinase inhibitors for multiple targets.

Founded a medicinal chemistry research organization with a goal of helping academic and industrial researchers rapidly, efficiently and practically identify and optimize early lead compounds for small-molecule drug discovery projects. Worked on developing a technology to reduce the scale of chemical synthesis, using functionalized magnetic nanoparticles, to allow medicinal chemists to generate hundreds of compounds from just a few milligrams of a complex organic intermediate. • Signed a sponsored research agreement with the University of Kansas to conduct the early-stage proof of concept research in the laboratory of Prof. Paul R. Hanson. • Worked directly in the lab and supervised a postdoctoral researcher to develop the technology.•Jointly wrote with Prof. Hanson a research grant proposal which was successfully funded through the University of Kansas Innovations and Collaborations department.• Built relationships that enabled the company to locate within the Bioscience and Technology Business Center at the University of Kansas. • Wrote SBIR grant proposals to fund the operations.

Alameda, California, Us

Led a group of 12-15 researchers within the medicinal chemistry department with the primary mission of conducting lead optimization/lead validation studies of oncolytic, metabolic, and inflammation targets. Worked with members of other departments within discovery to shape the research directions and meet the timelines of those projects. Provided diversity library support for all teams within medicinal chemistry in South San Francisco. • Led a team that discovered XL499, a potent inhibitor of PI3Kδ, which became a development candidate (DC) and was later licensed to Merck & Co. for $12 million dollars. • Led a team that discovered XL019, a potent inhibitor of JAK2, which became a development candidate (DC) and was later partnered to Bristol-Myers Squibb for $20 million dollars.• Led a team that discovered XL413, a potent inhibitor of Cdc7, which reached DC status. • Contributed compounds that led to the discovery of DC candidate XL518, a potent inhibitor of MEK1.• Contributed library support that impacted the research directions of DC candidates XL147 (general PI3K inhibitor), XL888 (an HSP90 inhibitor), and XL541 (an S1P1R antagonist). • Led a team that discovered a proof of concept compound for the inhibition of glucosoyl ceramide synthase (GCS), a promising target for the treatment of diabetes. • Implemented an HT-Synthesis program within the medicinal chemistry deptartment to generate high-purity quality compound libraries for research in amounts that enabled biochemical, cellular, and pharmacologic testing within one week of submission.

Alameda, California, Us

Led the combinatorial chemistry department to complete the company’s rapid compound library growth to 4 million compounds and finished outside library collaborations with Schering-Plough, Merck, Elan Pharmaceuticals, Scios, and Cytokinetics. Managed all aspects of those collaborations from library scheme development, outsourcing, conducting quarterly JRC meetings, compound production and delivery. Oversaw a group of 28 researchers and managed budgets in excess of 10 million dollars (US) annually.• Successfully met compound deliverables (> 350,000 compounds annually) with outside partners. • Added over 1 million compounds to the internal Exelixis compound library in both 2003 and 2004. • Completely redesigned the library production facility to improve efficiency, productivity, and safety. The facility reached a capacity, of greater then 360 plates of compounds per week, without the need to run multiple shifts of workers. • Implemented changes to the library scheme development process that resulted in faster modifications to problematic chemistries and improved the timely delivery of template materials for library production to meet yearly goals. • Added additional Ph.D. chemists to troubleshoot scheme chemistries.

Alameda, California, Us

Managed the combinatorial synthesis department as the company solidified its goal of building a diverse compound collection of several million compounds to aid its drug discovery efforts. In addition to in-house compound synthesis, was responsible for compound libraries being generated in collaboration with Schering-Plough, Elan Pharmaceuticals, Scios, and Cytokinetics. Oversaw a group of 20 researchers and managed budgets in excess of 8 million dollars (US) annually. • Successfully met all compound deliverables (> 300,000 compounds annually) with outside partners. • Added over 700,000 compounds to the internal Exelixis library. • Hired and oversaw the initial Ph.D. chemists into the combichem group to troubleshoot chemistries being used and to accelerate go/no go decisions on library projects. • Implemented the new block and resin dispensing technologies as well as modifications to the general process that improved productivity.• Designed library schemes as part of a group of scientists. • Expanded the range of chemistries available in our diversification process to include reductive aminations and nucleophilic aromatic substitutions.

Alameda, California, Us

One of the first chemists at Exelixis and worked primary to build its compound collection through solution-phase parallel synthesis, as the company made its initial steps in transforming itself from a genomics to a drug discovery company. (Company acquired MetaXen.)•Set up the initial combinatorial chemistry lab at Exelixis by working with scientists at Bristol-Myers Squibb to duplicate their technology in-house, as part of a technology transfer deal.•Validated the general solution-phase reactions that would form the final steps of our library process.•To increase throughput, replaced the initial block technology with one consisting of disposable off the shelf components.•Collaborated in the design of a custom block technology to increase throughput.•Oversaw a team that generated our first 100,000 compounds in two months using the modified technology.• Oversaw the first full year of library production that added several hundred thousand compounds to the library with a group of 12 research associates.

MetaXen LLC, South San Francisco, CaliforniaWorked as a medicinal chemist as part of a multidisciplinary team of chemists, biologists and computational chemists working toward the discovery of inhibitors of PAI/TPA complex formation.

Us

Developed new methods for synthesizing organic compounds on the solid-phase for this startup company which was later acquired by Amgen.• Developed a new reagent (now commercially available) that enabled the solid-phase synthesis of 2-aminothiazoles and guanidine compounds. • Prepared a new linker for immobilizing tertiary amines on resin.• Generated compound libraries targeted at PPARγ.

Pasadena, Ca, Us

Co-developed methods for expressing membrane-bound proteins containing unnatural amino acids in intact cells. Utilized these methods, in conjunction with basic electrophysiological techniques (2-electrode voltage clamp, patch clamp), to study the structure/function relationships of ligand-gated ion channels. • Determined the role of conserved ligand binding site aromatic residues played in the pharmacology of the nicotinic acetylcholine receptor.• Elucidated interactions between conserved leucine residues in the pore region of the nicotinic acetylcholine receptor.

Ph.D., Chemistry

Certificate Of Completion, Full-Stack Flex Coding

B.S. (With Honors), Chemistry